Cytopath Biopsy Lab Inc.

Cytopath Biopsy Lab Inc., operating as Cblpath, delivers specialized molecular diagnostic laboratory testing services to the federal government as a prime contractor, with a narrow and exclusive focus on ThyroSeq genomic sequencing technology for thyroid cancer risk assessment in veteran and military populations. The company competes on full-and-open basis without set-aside designations across all 110 recent awards, positioning itself as a competitive vendor offering proprietary diagnostic capabilities rather than a set-aside-dependent entity.

Cblpath's portfolio is dominated by ThyroSeq molecular diagnostic testing—a proprietary genetic sequencing assay that analyzes mutations in thyroid nodules to assess malignancy risk and inform clinical decision-making. Representative work includes a $2.56 million purchase order from Department of Veterans Affairs Veterans Integrated Service Network 22 for thyroid cancer screening services (October 2023 through October 2026); a $669.7 million firm fixed-price purchase order from VISN 21 for ThyroSeq V3 Classifier CPT testing (August 2024 through August 2029); and a $607.5 thousand sole-source purchase order from VISN 7 for thyroid molecular testing at the Atlanta VA Medical Center (May 2024 through April 2029). The vendor also holds a $200 thousand purchase order from the National Institute of Diabetes and Digestive and Kidney Diseases for ThyroSeq molecular diagnostic testing with a May 2022 through March 2027 performance period. All federal contracts employ firm fixed-price structures without set-asides, reflecting competitive positioning as a specialized provider of the exclusive ThyroSeq technology platform.

Customer concentration is heavy within the VA system and Defense Health Agency. The top five funding organizations account for 74 percent of combined potential value: Defense Health Agency leads with 12 awards worth $9.8 million; VISN 1 holds 7 awards worth $5 million; VISN 6 accounts for 20 awards worth $4.2 million; VISN 22 carries 5 awards worth $4.1 million; and VISN 2 represents 12 awards worth $3.2 million. By award count, VISN 6 leads with 20 awards, followed by VISN 2 and Defense Health Agency at 12 awards each. This concentration reflects Cblpath's role as sole or primary provider of ThyroSeq testing across regional VA healthcare networks, with performance locations spanning Port Chester and Rye Brook, New York; San Francisco, California; Memphis, Tennessee; Boise, Idaho; Indianapolis, Indiana; and multiple North Carolina and Virginia facilities.

The vendor holds nine active parent vehicles, all structured as single-award blanket purchase agreements or indefinite delivery contracts with VA regional networks and Defense Health Agency. The $2.88 million BPA with VISN 1 (September 2021 through September 2026) represents the largest vehicle, followed by a $2.25 million BPA with VISN 6 (October 2025 through September 2030) and a $1.8 million IDC with VISN 2 (February 2023 through February 2028). Additional vehicles include a $669.7 million purchase order with VISN 21 for ThyroSeq V3 Classifier testing, a $607.5 thousand purchase order with VISN 7 for thyroid molecular testing, and a $513.1 thousand purchase order with VISN 9 for thyroid cancer testing—all structured as firm fixed-price contracts running multiple years. The company issued no subcontracts across its 110 awards; all work is performed in-house as prime contractor.

Activity has accelerated year over year, growing from 14 awards in 2022 to 19 in 2024, with 18 awards in 2025. Twenty awards representing $4.5 million in combined potential value reach ultimate completion within the next twenty-four months, creating recompete exposure tied to renewal of VISN-specific BPA and IDC vehicles. SCI-reported invoiced revenue was $1 million across FY2023–FY2024, with $664 thousand recorded in FY2023 and $360 thousand in FY2024; SCI coverage is sparse because most Cblpath work is structured as goods (testing kits and reagents) or falls below the $150 thousand reporting threshold. Government-paid hourly rates on the limited SCI-reportable service contracts ranged from $666.67 per hour (10th percentile) through $5,666.67 per hour (median) to $54,666.66 per hour (90th percentile), reflecting the mix of routine testing labor and specialized professional services embedded in the company's pricing. The vendor operates without named subcontractors; sub-hours engagement is zero across the prime portfolio. Cblpath's business model centers on direct delivery of proprietary diagnostic services rather than subcontracting or team-based delivery.